51
|
Ko YA, Billheimer JT, Lyssenko NN, Kueider-Paisley A, Wolk DA, Arnold SE, Leung YY, Shaw LM, Trojanowski JQ, Kaddurah-Daouk RF, Kling MA, Rader DJ. ApoJ/Clusterin concentrations are determinants of cerebrospinal fluid cholesterol efflux capacity and reduced levels are associated with Alzheimer's disease. Alzheimers Res Ther 2022; 14:194. [PMID: 36572909 PMCID: PMC9791777 DOI: 10.1186/s13195-022-01119-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2022] [Accepted: 11/06/2022] [Indexed: 12/27/2022]
Abstract
BACKGROUND Alzheimer's disease (AD) shares risk factors with cardiovascular disease (CVD) and dysregulated cholesterol metabolism is a mechanism common to both diseases. Cholesterol efflux capacity (CEC) is an ex vivo metric of plasma high-density lipoprotein (HDL) function and inversely predicts incident CVD independently of other risk factors. Cholesterol pools in the central nervous system (CNS) are largely separate from those in blood, and CNS cholesterol excess may promote neurodegeneration. CEC of cerebrospinal fluid (CSF) may be a useful measure of CNS cholesterol trafficking. We hypothesized that subjects with AD and mild cognitive impairment (MCI) would have reduced CSF CEC compared with Cognitively Normal (CN) and that CSF apolipoproteins apoA-I, apoJ, and apoE might have associations with CSF CEC. METHODS We retrieved CSF and same-day ethylenediaminetetraacetic acid (EDTA) plasma from 108 subjects (40 AD; 18 MCI; and 50 CN) from the Center for Neurodegenerative Disease Research biobank at the Perelman School of Medicine, University of Pennsylvania. For CSF CEC assays, we used N9 mouse microglial cells and SH-SY5Y human neuroblastoma cells, and the corresponding plasma assay used J774 cells. Cells were labeled with [3H]-cholesterol for 24 h, had ABCA1 expression upregulated for 6 h, were exposed to 33 μl of CSF, and then were incubated for 2.5 h. CEC was quantified as percent [3H]-cholesterol counts in medium of total counts medium+cells, normalized to a pool sample. ApoA-I, ApoJ, ApoE, and cholesterol were also measured in CSF. RESULTS We found that CSF CEC was significantly lower in MCI compared with controls and was poorly correlated with plasma CEC. CSF levels of ApoJ/Clusterin were also significantly lower in MCI and were significantly associated with CSF CEC. While CSF ApoA-I was also associated with CSF CEC, CSF ApoE had no association with CSF CEC. CSF CEC is significantly and positively associated with CSF Aβ. Taken together, ApoJ/Clusterin may be an important determinant of CSF CEC, which in turn could mitigate risk of MCI and AD risk by promoting cellular efflux of cholesterol or other lipids. In contrast, CSF ApoE does not appear to play a role in determining CSF CEC.
Collapse
|
52
|
Ríos AS, Oxenford S, Neudorfer C, Butenko K, Li N, Rajamani N, Boutet A, Elias GJB, Germann J, Loh A, Deeb W, Wang F, Setsompop K, Salvato B, Almeida LBD, Foote KD, Amaral R, Rosenberg PB, Tang-Wai DF, Wolk DA, Burke AD, Salloway S, Sabbagh MN, Chakravarty MM, Smith GS, Lyketsos CG, Okun MS, Anderson WS, Mari Z, Ponce FA, Lozano AM, Horn A. Optimal deep brain stimulation sites and networks for stimulation of the fornix in Alzheimer's disease. Nat Commun 2022; 13:7707. [PMID: 36517479 PMCID: PMC9751139 DOI: 10.1038/s41467-022-34510-3] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2021] [Accepted: 10/27/2022] [Indexed: 12/15/2022] Open
Abstract
Deep brain stimulation (DBS) to the fornix is an investigational treatment for patients with mild Alzheimer's Disease. Outcomes from randomized clinical trials have shown that cognitive function improved in some patients but deteriorated in others. This could be explained by variance in electrode placement leading to differential engagement of neural circuits. To investigate this, we performed a post-hoc analysis on a multi-center cohort of 46 patients with DBS to the fornix (NCT00658125, NCT01608061). Using normative structural and functional connectivity data, we found that stimulation of the circuit of Papez and stria terminalis robustly associated with cognitive improvement (R = 0.53, p < 0.001). On a local level, the optimal stimulation site resided at the direct interface between these structures (R = 0.48, p < 0.001). Finally, modulating specific distributed brain networks related to memory accounted for optimal outcomes (R = 0.48, p < 0.001). Findings were robust to multiple cross-validation designs and may define an optimal network target that could refine DBS surgery and programming.
Collapse
Grants
- P30 AG066507 NIA NIH HHS
- P30 AG072979 NIA NIH HHS
- R01 MH130666 NIMH NIH HHS
- Deutsche Forschungsgemeinschaft (German Research Foundation)
- Received grants and personal fees from Medtronic and Boston Scientific, grants from Abbott/St. Jude, and Functional Neuromodulation outside the submitted work.
- Received grants from Functional Neuromodulation during conduct of this study, grants and personal fees from Avid/Lily, and Merck, personal fees from Jannsen, GE Healthcare, Biogen and Neuronix outside the submitted work.
- Receives personal fees from Elsai, Lilly, Roche Novartis and Biogen outside the submitted work.
- Received personal fees from Allergan, Biogen, Roche-Genentech, Cortexyme, Bracket, Sanofi, and other type of support from Brain Health Inc and uMethod Health outside of the submitted work.
- Received grants from Functional Neuromodulation Inc. during conduct of this study, from Avanir and Eli Lily and NFL Benefits Office outside of the submitted work.
- Received grants from NIH, Tourette Association of America Grant, Parkinson’s Alliance, Smallwood Foundation, and personal fees from Parkinson’s Foundation Medical Director, Books4Patients, American Academy of Neurology, Peerview, WebMD/Medscape, Mededicus, Movement Disorders Society, Taylor and Francis, Demos, Robert Rose and non-financial support from Medtronic outside of the submitted work.
- Received grants from Medtronic and Functional Neuromodulation during conduct of this study, personal fees from Medtronic, St. Jude, Boston Scientific, and Functional Neuromodulation outside of submitted work
- Deutsches Zentrum für Luft- und Raumfahrt (German Centre for Air and Space Travel)
- National Institutes of Health (R01 13478451, 1R01NS127892-01 & 2R01 MH113929) New Venture Fund (FFOR Seed Grant).
Collapse
|
53
|
Tropea TF, Waligorska T, Xie SX, Nasrallah IM, Cousins KAQ, Trojanowski JQ, Grossman M, Irwin DJ, Weintraub D, Lee EB, Wolk DA, Chen‐Plotkin AS, Shaw LM. Plasma phosphorylated tau181 predicts cognitive and functional decline. Ann Clin Transl Neurol 2022; 10:18-31. [PMID: 36518085 PMCID: PMC9852389 DOI: 10.1002/acn3.51695] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2022] [Revised: 10/11/2022] [Accepted: 10/31/2022] [Indexed: 12/23/2022] Open
Abstract
OBJECTIVE To determine if plasma tau phosphorylated at threonine 181 (p-tau181) distinguishes pathology-confirmed Alzheimer's disease (AD) from normal cognition (NC) adults, to test if p-tau181 predicts cognitive and functional decline, and to validate findings in an external cohort. METHODS Thirty-one neuropathology-confirmed AD cases, participants with clinical diagnoses of mild cognitive impairment (MCI, N = 91) or AD dementia (N = 64), and NC (N = 241) had plasma collected at study entry. The clinical diagnosis groups had annual cognitive (Mini-Mental State Examination, MMSE) and functional (Clinical Dementia Rating Scale, CDR) measures. NC (N = 70), MCI (N = 75), and AD dementia (N = 50) cases from the Alzheimer's Disease Neuroimaging Initiative (ADNI) were used as a validation cohort. Plasma p-tau181 was measured using the Quanterix SiMoA HD-X platform. RESULTS Plasma p-tau181 differentiated pathology-confirmed AD from NC with negative amyloid PET scans with an AUC of 0.93. A cut point of 3.44 pg/mL (maximum Youden Index) had a sensitivity of 0.77, specificity of 0.96. p-Tau181 values above the cut point were associated with the faster rate of decline in MMSE in AD dementia and MCI and a shorter time to a clinically significant functional decline in all groups. In a subset of MCI cases from ADNI, p-tau181 values above the cut point associated with faster rate of decline in MMSE, and a shorter time to a clinically significant functional decline and conversion to dementia. INTERPRETATION Plasma p-tau181 differentiates AD pathology cases from NC with high accuracy. Higher levels of plasma p-tau181 are associated with faster cognitive and functional decline.
Collapse
|
54
|
Spencer BE, Irwin DJ, Van Deerlin VM, Lee EB, Elman L, Quinn C, Grossman M, Wolk DA, McMillan CT. Modules of genotypic variance reflect heterogeneity across TDP‐43 proteinopathies. Alzheimers Dement 2022. [DOI: 10.1002/alz.066820] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
55
|
Xiong C, Wolk DA, Lah JJ, Gleason CE, Roberson ED, Benzinger TL, Schindler SE, Fagan AM, Hassenstab JJ, Moulder KL, Balls‐Berry JE, Sperling RA, Johnson KA, Levey AI, Johnson SC, Luo J, Gremminger E, Agboola F, Grant EA, Ances BM, Gordon BA, Hornbeck RC, Massoumzadeh P, Keefe SJ, Dierker D, Gray JD, Andrews J, Henson RL, Streitz M, Manzanares C, Qiu D, Mechanic‐Hamilton D, Stites SD, Shaw LM, Midgett S, Morris JC. SORTOUT‐AB: A Study of Race to Understand Alzheimer Biomarkers. Alzheimers Dement 2022. [DOI: 10.1002/alz.066301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
56
|
Kim B, Suh E, Nguyen AT, Prokop S, Mikytuck B, Olatunji OA, Robinson JL, Grossman M, Phillips JS, Irwin DJ, Mechanic-Hamilton D, Wolk DA, Trojanowski JQ, McMillan CT, Van Deerlin VM, Lee EB. TREM2 risk variants are associated with atypical Alzheimer's disease. Acta Neuropathol 2022; 144:1085-1102. [PMID: 36112222 PMCID: PMC9643636 DOI: 10.1007/s00401-022-02495-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2022] [Revised: 09/07/2022] [Accepted: 09/08/2022] [Indexed: 01/26/2023]
Abstract
Alzheimer's disease (AD) has multiple clinically and pathologically defined subtypes where the underlying causes of such heterogeneity are not well established. Rare TREM2 variants confer significantly increased risk for clinical AD in addition to other neurodegenerative disease clinical phenotypes. Whether TREM2 variants are associated with atypical clinical or pathologically defined subtypes of AD is not known. We studied here the clinical and pathological features associated with TREM2 risk variants in an autopsy-confirmed cohort. TREM2 variant cases were more frequently associated with non-amnestic clinical syndromes. Pathologically, TREM2 variant cases were associated with an atypical distribution of neurofibrillary tangle density with significantly lower hippocampal NFT burden relative to neocortical NFT accumulation. In addition, NFT density but not amyloid burden was associated with an increase of dystrophic microglia. TREM2 variant cases were not associated with an increased prevalence, extent, or severity of co-pathologies. These clinicopathological features suggest that TREM2 variants contribute to clinical and pathologic AD heterogeneity by altering the distribution of neurofibrillary degeneration and tau-dependent microglial dystrophy, resulting in hippocampal-sparing and non-amnestic AD phenotypes.
Collapse
|
57
|
Vogel JW, Strandberg O, Gaiteri C, Cieslak M, Covitz S, Wolk DA, Davatzikos C, Hansson O, Satterthwaite T. An autopsy‐validated, easily deployable MRI predictor of Alzheimer’s disease tau pathology. Alzheimers Dement 2022. [DOI: 10.1002/alz.065959] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
58
|
Young AL, Vogel JW, Robinson J, McMillan CT, Ossenkoppele R, Wolk DA, Irwin DJ, Elman L, Grossman M, Lee VM, Lee EB, Trojanowski JQ, Hansson O. Empirical pathological staging and subtyping of TDP‐43 proteinopathies. Alzheimers Dement 2022. [DOI: 10.1002/alz.063390] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
59
|
McMillan CT, Adhikari B, Farrell KW, Wolk DA, Lee EB, Crary JF, Johnson FB. Short Telomeres Associate with Hyperphosphorylated Tau Burden in Primary Age‐Related Tauopathy. Alzheimers Dement 2022. [DOI: 10.1002/alz.067329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
60
|
Phillips JS, Burke SE, Cousins KAQ, Arezoumandan S, Ohm DT, Chen M, Cook P, Dubroff JG, Nasrallah IM, McMillan CT, Grossman M, Wolk DA, Irwin DJ. Tau accumulation and degeneration differ across functional networks in atypical Alzheimer's disease phenotypes. Alzheimers Dement 2022. [DOI: 10.1002/alz.064638] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
61
|
Khandelwal P, Duong MT, Chung E, Sadaghiani S, Lim SA, Ravikumar S, Arezoumandan S, Peterson C, Bedard ML, Capp N, Ittyerah R, Migdal E, Choi G, Kopp E, Patino BL, Hasan E, Li J, Prabhakaran K, Mizsei G, Gabrielyan M, Schuck T, Robinson JL, Ohm DT, Nasrallah IM, Lee EB, Trojanowski JQ, McMillan CT, Grossman M, Irwin DJ, Tisdall DM, Das SR, Wisse LEM, Wolk DA, Yushkevich PA. Deep Learning for Ultra High Resolution T2‐weighted 7 Tesla
Ex vivo
Magnetic Resonance Imaging Reveals Differential Subcortical Atrophy across Neurodegenerative Diseases. Alzheimers Dement 2022. [DOI: 10.1002/alz.062628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
62
|
Ezzati A, Petersen KK, Nallapu BT, Davatzikos C, Wolk DA, Rabin L, Habeck C, Hall CB, Lipton RB. Targeting the Correct Population for Trials: A Post‐hoc Analysis of Trial of Solanezumab for Mild Dementia Due to Alzheimer’s disease. Alzheimers Dement 2022. [DOI: 10.1002/alz.065995] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
63
|
Sadaghiani S, Ravikumar S, Ittyerah R, Lim SA, Chung E, Bedard ML, Xie L, Das SR, Schuck T, Grossman M, Lee EB, Tisdall DM, Prabhakaran K, Detre JA, Mizsei G, Trojanowski JQ, Irwin DJ, Wisse LEM, Wolk DA, Yushkevich PA. Linking histology to post‐mortem 7T MRI measures of neurodegeneration. Alzheimers Dement 2022. [DOI: 10.1002/alz.066155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
64
|
Govindarajan ST, Mamourian E, Erus G, Abdulkadir A, Melhem R, Doshi J, Pomponio R, Tosun D, Bilgel M, An Y, Sotiras A, Marcus DS, LaMontagne PJ, Espeland MA, Masters CL, Maruff P, Launer LJ, Fripp J, Johnson SC, Morris JC, Albert MS, Bryan RN, Resnick SM, Habes M, Shou H, Wolk DA, Nasrallah IM, Davatzikos C. Machine‐learning based MRI neuro‐anatomical signatures associated with cardiovascular and metabolic risk factors. Alzheimers Dement 2022. [DOI: 10.1002/alz.061530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
65
|
Mechanic-Hamilton D, Halberstadter K, Lydon S, Liebenberg E, Wolk DA. At-Home Data Collection with an App-Based Cognitive Assessment for Detecting Memory and Executive Functioning Changes in Aging and Pre-Clinical AD. Alzheimers Dement 2022; 18 Suppl 2:e067620. [PMID: 36537488 DOI: 10.1002/alz.067620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
BACKGROUND Mobile, valid and engaging cognitive assessments are essential for detecting and tracking change in research participants and patients at risk for Alzheimer's Disease and Related Dementias (ADRDs). This pilot study aims to determine the feasibility of at-home, app-based memory and executive functioning tasks included in the mobile cognitive app performance platform (mCAPP), to detect cognitive changes associated with aging and preclinical AD. METHOD The mCAPP includes three gamified tasks (Figure 1): (1) a "concentration" memory task that includes learning and matching hidden card pairs with increasing memory load, pattern separation features (lure vs. non-lure), and spatial memory (2) a stroop-like task ("brick drop") with speeded word and color identification and response inhibition components and (3) a digit-symbol coding-like task ("space imposters") with increasing pairs and incidental learning components. Participants also completed the NACC UDS3, additional paper and pencil tests, and NIH Toolbox measures. Participants used the mCAPP at home for two weeks. Participants included sixteen older adults (56% female; age=71.4±5.0, education=16.4±3.1; 63% White, 31% Black, 6% Multiracial) without cognitive impairment enrolled in the Penn ADRC cohort. RESULTS Participants played 12.1±4 times over two weeks, with 15/16 playing more than the assigned sessions. Almost all participants (88%) used a smartphone, but few (31%) played games on their phone. Usability rating was 6.2±0.7 (1-7 scale) and most participants reported task difficulty was just right (75%-81%). All tasks showed lower performance with increasing age and brick drop inhibition and space imposters also correlated with education (p's<0.05). Concentration performance correlated with UDS3 memory measures (p's<0.05, Figure 2). Brick drop performance correlated with measures of attention and executive functioning (p's<0.05, Figure 3). Space imposters correlated with the Digit Symbol Substitution Test (p<0.001, Figure 4). Some participants performed similarly across AM and PM sessions, while others showed differential performance. Initial change scores from the first to second session and from the 2nd to the last sessions did not show significant change. CONCLUSION This pilot study shows acceptability and usability of the app for at-home use. Performance across measures indicate initial reliability and validity of mCAPP with continued data collection with a larger sample needed.
Collapse
|
66
|
Ravikumar S, Denning A, Lim SA, Chung E, Ittyerah R, Wisse LEM, Xie L, Das SR, Robinson J, Schuck T, Grossman M, Lee EB, Tisdall DM, Mizsei G, Artacho‐Perula E, Martin MMIDO, Jimenez MA, Munoz M, Romero FJM, Rabal PM, Sanchez SC, Gonzalez JCD, Prieto R, Parada MC, Irwin DJ, Trojanowski JQ, Wolk DA, Insausti R, Yushkevich PA. Combining high‐resolution ex vivo MRI and histopathology to identify medial temporal lobe atrophy patterns specific to tau pathology in Alzheimer’s Disease. Alzheimers Dement 2022. [DOI: 10.1002/alz.065784] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
67
|
Wen J, Cui Y, Yang Z, Bao J, Chen J, Erus G, Abdulkadir A, Mamourian E, Singh A, Yang S, Fan Y, Saykin AJ, Thompson PM, Jun GR, Ritchie MD, Shen L, Wolk DA, Shou H, Nasrallah IM, Davatzikos C. Genetic heterogeneity of four MCI/AD neuroanatomical dimensions discovered via deep learning. Alzheimers Dement 2022. [DOI: 10.1002/alz.065223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
68
|
Arezoumandan S, Xie SX, Cousins KAQ, Mechanic-Hamilton DJ, Peterson CS, Huang CY, Ohm DT, Ittyerah R, McMillan CT, Wolk DA, Yushkevich P, Trojanowski JQ, Lee EB, Grossman M, Phillips JS, Irwin DJ. Regional distribution and maturation of tau pathology among phenotypic variants of Alzheimer's disease. Acta Neuropathol 2022; 144:1103-1116. [PMID: 35871112 PMCID: PMC9936795 DOI: 10.1007/s00401-022-02472-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2022] [Revised: 07/02/2022] [Accepted: 07/14/2022] [Indexed: 01/26/2023]
Abstract
Alzheimer's disease neuropathologic change (ADNC) is clinically heterogenous and can present with a classic multidomain amnestic syndrome or focal non-amnestic syndromes. Here, we investigated the distribution and burden of phosphorylated and C-terminally cleaved tau pathologies across hippocampal subfields and cortical regions among phenotypic variants of Alzheimer's disease (AD). In this study, autopsy-confirmed patients with ADNC, were classified into amnestic (aAD, N = 40) and non-amnestic (naAD, N = 39) groups based on clinical criteria. We performed digital assessment of tissue sections immunostained for phosphorylated-tau (AT8 detects pretangles and mature tangles), D421-truncated tau (TauC3, a marker for mature tangles and ghost tangles), and E391-truncated tau (MN423, a marker that primarily detects ghost tangles), in hippocampal subfields and three cortical regions. Linear mixed-effect models were used to test regional and group differences while adjusting for demographics. Both groups showed AT8-reactivity across hippocampal subfields that mirrored traditional Braak staging with higher burden of phosphorylated-tau in subregions implicated as affected early in Braak staging. The burden of phosphorylated-tau and TauC3-immunoreactive tau in the hippocampus was largely similar between the aAD and naAD groups. In contrast, the naAD group had lower relative distribution of MN423-reactive tangles in CA1 (β = - 0.2, SE = 0.09, p = 0.001) and CA2 (β = - 0.25, SE = 0.09, p = 0.005) compared to the aAD. While the two groups had similar levels of phosphorylated-tau pathology in cortical regions, there was higher burden of TauC3 reactivity in sup/mid temporal cortex (β = 0.16, SE = 0.07, p = 0.02) and MN423 reactivity in all cortical regions (β = 0.4-0.43, SE = 0.09, p < 0.001) in the naAD compared to aAD. In conclusion, AD clinical variants may have a signature distribution of overall phosphorylated-tau pathology within the hippocampus reflecting traditional Braak staging; however, non-amnestic AD has greater relative mature tangle pathology in the neocortex compared to patients with clinical amnestic AD, where the hippocampus had greatest relative burden of C-terminally cleaved tau reactivity. Thus, varying neuronal susceptibility to tau-mediated neurodegeneration may influence the clinical expression of ADNC.
Collapse
|
69
|
Khandelwal P, Sadaghiani S, Chung E, Lim SA, Duong MT, Ravikumar S, Arezoumandan S, Peterson C, Bedard ML, Capp N, Ittyerah R, Migdal E, Choi G, Kopp E, Patino BL, Hasan E, Li J, Prabhakaran K, Mizsei G, Gabrielyan M, Schuck T, Robinson J, Ohm DT, Lee EB, Trojanowski JQ, McMillan CT, Grossman M, Irwin DJ, Tisdall DM, Das SR, Wisse LEM, Wolk DA, Yushkevich PA. Deep learning pipeline for cortical gray matter segmentation and thickness analysis in Ultra High Resolution T2w 7 Tesla
Ex vivo
MRI across neurodegenerative diseases reveals associations with underlying neuropathology. Alzheimers Dement 2022. [DOI: 10.1002/alz.065737] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
70
|
Roalf DR, Robinson H, Kesselring I, Jee J, Mordy A, Ruparel K, Meeks J, Wolk DA, Nanga RPR, Gur RC, Reddy R. Low and asymmetrical hippocampal glutamate levels in healthy older adults. Alzheimers Dement 2022. [DOI: 10.1002/alz.065278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
71
|
Dong M, Xie L, Wang J, Das SR, Wolk DA, Yushkevich PA. Deep Learning Registration with Scan‐temporal Consistency May Improve Detection of Alzheimer’s Disease Progression. Alzheimers Dement 2022. [DOI: 10.1002/alz.068343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
72
|
Taghvaei M, Cook P, Khandelwal P, Shakibajahromi B, Sadaghiani S, Das SR, Brown C, Tackett W, Dolui S, Shinohara RT, Wolk DA, Detre JA. Mechanisms of Cognitive Decline due to White Matter Lesions in Cognitively Intact Older Adults. Alzheimers Dement 2022. [DOI: 10.1002/alz.069332] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
73
|
Wisse LEM, Xie L, Lyu X, Das SR, de Flores R, Lane J, Yushkevich PA, Wolk DA, Initiative DN. PART is part of SNAP‐MCI. Alzheimers Dement 2022. [DOI: 10.1002/alz.064439] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
74
|
Lyu X, Duong MT, Xie L, Richardson H, de Flores R, DiCalogero M, McMillan CT, Robinson J, Trojanowski JQ, Grossman M, Lee EB, Irwin DJ, Dickerson BC, Xie SX, Nasrallah IM, Yushkevich PA, Wolk DA, Das SR. Tau‐Neurodegeneration mismatch reveals vulnerability and resilience in Alzheimer’s continuum and Non‐Alzheimer’s pathophysiology. Alzheimers Dement 2022. [DOI: 10.1002/alz.062542] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
75
|
Xie L, Wisse LEM, Das SR, Lyu X, de Flores R, Yushkevich PA, Wolk DA. Tau burden is associated with cross‐sectional and longitudinal neurodegeneration in the medial temporal lobe in cognitively normal individuals. Alzheimers Dement 2022. [DOI: 10.1002/alz.067095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|